scholarly journals 3D virtual and printed reconstructions of renal cell cancer with venous thrombus extension for surgical planning. Phase III NCT03738488

2021 ◽  
Vol 33 ◽  
pp. S313-S314
Author(s):  
I. Rivero Belenchón ◽  
C.B. Congregado Ruíz ◽  
G. Gómez Ciriza ◽  
V. Gómez Dos Santos ◽  
C. Galvez Garcia ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Surgical Planning ◽  
Cell Cancer ◽  
Phase Iii ◽  
Venous Thrombus ◽  
Planning Phase

Obtaining a personalised 3D model of renal cell cancer with venous thrombus extension to aid in surgical planning and simulation

2019 ◽  
Vol 18 (1) ◽  
pp. e1752-e1753
Author(s):  
I. Rivero Belenchón ◽  
C.B. Congregado Ruiz ◽  
V. Gómez Dos Santos ◽  
C. Galvez ◽  
C. González Gordaliza ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Surgical Planning ◽  
3D Model ◽  
Cell Cancer ◽  
Venous Thrombus

How to obtain a personalised 3D model of renal cell cancer with venous thrombus extension for surgical planning and simulation?

2019 ◽  
Vol 18 (11) ◽  
pp. e3554-e3555
Author(s):  
I. Rivero Belenchón ◽  
C.B. Congregado Ruíz ◽  
G. Gómez Ciriza ◽  
V. Gómez Dos Santos ◽  
C. Gálvez García ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Surgical Planning ◽  
3D Model ◽  
Cell Cancer ◽  
Venous Thrombus

scholarly journals 1848P Feasible 3D printed models of renal cell cancer with venous thrombus extension for surgical planning and simulation: Phase I NCT03738488

2021 ◽  
Vol 32 ◽  
pp. S1246-S1247
Author(s):  
I. Rivero Belenchon ◽  
C.B. Congregado Ruiz ◽  
G. Gomez Ciriza ◽  
V. Gómez Dos Santos ◽  
C. Galvez Garcia ◽  
...  
Keyword(s):  
Phase I ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Surgical Planning ◽  
Cell Cancer ◽  
Venous Thrombus ◽  
3D Printed

499: Sorafenib (Bay 43-9006) in Patients with Advanced Renal Cell Cancer (MRCC) as Second Line Therapy-Unicentric Results of an Multicentric Randomised Phase III Trial of the Multi Multi-Kinase Inhibitor

2007 ◽  
Vol 177 (4S) ◽  
pp. 166-167
Author(s):  
Michael D. Staehler ◽  
Nicolas Haseke ◽  
Gita M. Schoeppler ◽  
Thomas Stadler ◽  
Anno Graser ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Cell Cancer ◽  
Phase Iii ◽  
Second Line ◽  
Second Line Therapy ◽  
Phase Iii Trial ◽  
Line Therapy ◽  
Advanced Renal Cell Cancer

A randomized phase III Trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4607-4607 ◽  
Author(s):  
N. M. Tannir ◽  
X. Wang ◽  
C. S. Ng ◽  
V. A. Poulter ◽  
P. Mathew ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Low Dose ◽  
Cell Cancer ◽  
Interferon Alfa ◽  
Phase Iii ◽  
Front Line ◽  
Phase Iii Trial ◽  
Line Therapy ◽  
Intermediate Dose

Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4605-4605 ◽  
Author(s):  
R. Passalacqua ◽  
C. Buzio ◽  
M. Dalla Chiesa ◽  
R. Camisa ◽  
C. Porta ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Multicentre Trial ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Phase Iii ◽  
Metastatic Renal Cell Cancer

scholarly journals Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial

2019 ◽  
Vol 9 (4) ◽  
pp. 510-525 ◽  
Author(s):  
A. Ari Hakimi ◽  
Martin H. Voss ◽  
Fengshen Kuo ◽  
Alejandro Sanchez ◽  
Ming Liu ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Phase Iii ◽  
Transcriptomic Profiling ◽  
Phase Iii Trial ◽  
Cancer Data

scholarly journals Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

Kidney Cancer ◽  
2019 ◽  
Vol 3 (2) ◽  
pp. 111-118 ◽  
Author(s):  
Timothy W. Synold ◽  
Melissa Plets ◽  
Catherine M. Tangen ◽  
Elisabeth I. Heath ◽  
Ganesh S. Palapattu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Phase Iii ◽  
Pharmacokinetic Analysis ◽  
Adjuvant Setting ◽  
Phase Iii Study

A randomized phase III Trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4607-4607
Author(s):  
N. M. Tannir ◽  
X. Wang ◽  
C. S. Ng ◽  
V. A. Poulter ◽  
P. Mathew ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Low Dose ◽  
Cell Cancer ◽  
Interferon Alfa ◽  
Phase Iii ◽  
Front Line ◽  
Phase Iii Trial ◽  
Line Therapy ◽  
Intermediate Dose

A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma

2020 ◽  
Vol 26 (4) ◽  
pp. 972-981 ◽  
Author(s):  
Emre Yekedüz ◽  
H. Arzu Yaşar ◽  
Güngör Utkan ◽  
Yüksel Ürün
Keyword(s):  
Clinical Trials ◽  
Brain Metastasis ◽  
Renal Cell Cancer ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Overall Response Rate ◽  
Cell Cancer ◽  
Local Treatment ◽  
Phase Iii ◽  
Phase Iii Clinical Trials

Aim To define the inclusion/exclusion status of patients with brain metastasis in phase-III clinical trials and the effect of systemic therapies in metastatic renal cell cancer patients with brain metastasis. Methods “kidney neoplasms”[MeSH Terms] OR (“kidney”[All Fields] AND “neoplasms”[All Fields]) OR “kidney neoplasms”[All Fields] OR (“kidney”[All Fields] AND “cancer”[All Fields]) OR “kidney cancer”[All Fields] AND “brain metastasis” were used for searching “PubMed” electronic database and “clinicaltrials.gov” website. Results Five of 19 landmark phase-III clinical trials included patients with stable or asymptomatic brain metastasis and there was no data about outcomes of brain metastasis. The effect of systemic therapy on prevention of brain metastasis in renal cell cancer was evaluated in four studies. Two studies showed that the incidence of brain metastasis decreased, while the other two studies showed no effect of antiangiogenic agents on the prevention of brain metastasis in patients with renal cell cancer. There were 10 trials regarding systemic therapy of renal cell cancer brain metastasis. The overall response rate improved through a combination of targeted therapies and local treatment. The results of the trials studying the effect of tyrosine kinase inhibitors without local treatment were controversial. None of the ongoing clinical trials included patients with active brain metastasis. Conclusion In metastatic renal cell cancer patients with brain metastasis, the overall response rate improved with the combination of targeted agents and local treatment. Further trials are needed to evaluate the effect of systemic treatment on the prevention or treatment of brain metastasis in patients with renal cell cancer.

Sign in / Sign up

Export Citation Format

Share Document